Print this page
immunotherapy
-
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Brain and Nervous System -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 2 Study of Dabrafenib with Trametinib after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG).
Protocol: 112302Applicable Disease Sites: Brain and Nervous System
-
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Leukemia, other -
ARAR2221: A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Protocol: 112405Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.
Protocol: 142202Applicable Disease Sites: Brain and Nervous System
-
NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Protocol: 142302Principal Investigator:
-
Nicholas DeNunzio
Applicable Disease Sites: Brain and Nervous System -
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.
Protocol: 152301Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Rectum -
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.
Protocol: 172404Principal Investigator:
-
Eugenia Girda
Applicable Disease Sites: Any Site -
Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.
Protocol: 192002Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Any Site -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
-
Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital